Market research
PHVS Pharvaris BV
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 3B
- P/E ratio
- Not available
- Analyst target
- 49.5772
- Dividend yield
- Not available
- Beta
- -2.33
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- NL00150005Y4
- Market cap
- 3B
- P/E ratio
- Not available
- Analyst target
- 49.5772
- Dividend yield
- Not available
- Beta
- -2.33
About
About Pharvaris BV
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PHVS discussion.
5 years, 4 months ago
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Pharvaris N.V. Ordinary Shares gets an overall score of 1/5.